This document is scheduled to be published in the Federal Register on 07/23/2019 and available online at https://federalregister.gov/d/2019-15568, and on govinfo.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby

given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be open to the public as indicated below, with attendance limited to space

available. Individuals who plan to attend and need special assistance, such as sign language

interpretation or other reasonable accommodations, should notify the Contact Person listed

below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract

proposals and the discussions could disclose confidential trade secrets or commercial property

such as patentable material, and personal information concerning individuals associated with the

grant applications and/or contract proposals, the disclosure of which would constitute a clearly

unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Drug Abuse

Date: September 5, 2019

Closed: 9:00 AM to 10:15 AM

Agenda: To review and evaluate grant applications and/or proposals

Place: National Institutes of Health

Neuroscience Center Building (NSC)

1

6001 Executive Boulevard

Rockville, MD 20852

Open: 10:30 AM to 4:30 PM

Agenda: This portion of the meeting will be open to the public for announcements and reports of

administrative, legislative, and program developments in the drug abuse field.

Place: National Institutes of Health

Neuroscience Center Building (NSC)

6001 Executive Boulevard

Rockville, MD 20852

Contact Person: Susan R.B. Weiss, PHD

Director

Division of Extramural Research

Office of the Director

National Institute on Drug Abuse, NIH, DHHS

6001 Executive Boulevard, NSC, Room 5274, MSC 9591

Rockville, MD 20892

301-443-6487

sweiss@nida.nih.gov

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested

individuals and representatives of organizations may submit a letter of intent, a brief description

of the organization represented, and a short description of the oral presentation. Only one

representative of an organization may be allowed to present oral comments and if accepted by

2

the committee, presentations may be limited to five minutes. Both printed and electronic copies

are requested for the record. In addition, any interested person may file written comments with

the committee by forwarding their statement to the Contact Person listed on this notice. The

statement should include the name, address, telephone number and when applicable, the business

or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page:

www.drugabuse.gov/NACDA/NACDAHome.html , where an agenda and any additional

information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction

Research Programs, National Institutes of Health, HHS)

Dated: July 17, 2019.

Melanie J. Pantoja,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2019-15568 Filed: 7/22/2019 8:45 am; Publication Date: 7/23/2019]

3